Villanova Investment Management Co LLC Has $500,000 Holdings in InMode Ltd. $INMD

Key Points

• Villanova Investment Management Co LLC has significantly reduced its stake in InMode Ltd. by 69.4%, holding only 28,162 shares valued at approximately $500,000 after selling 63,794 shares.
• During the first quarter, other institutional investors also adjusted their stakes, with Handelsbanken Fonder AB increasing its holdings by 34.3% and GAMMA Investing LLC raising its stake by an astounding 13,923.8%.
• InMode reported earnings per share of $0.47, which fell short of the expected $0.50, with quarterly revenue also missing estimates at $95.60 million against an expectation of $98.45 million.

Villanova Investment Management Co LLC trimmed its holdings in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 69.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,162 shares of the healthcare company's stock after selling 63,794 shares during the period. Villanova Investment Management Co LLC's holdings in InMode were worth $500,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. CWM LLC lifted its stake in InMode by 106.4% in the 1st quarter. CWM LLC now owns 2,369 shares of the healthcare company's stock valued at $42,000 after purchasing an additional 1,221 shares during the last quarter. Orion Capital Management LLC bought a new position in InMode in the 4th quarter valued at about $65,000. Summit Securities Group LLC bought a new position in InMode in the 1st quarter valued at about $70,000. Lazard Asset Management LLC raised its holdings in InMode by 6,128.7% in the 4th quarter. Lazard Asset Management LLC now owns 6,291 shares of the healthcare company's stock valued at $105,000 after acquiring an additional 6,190 shares during the period. Finally, XTX Topco Ltd bought a new position in InMode in the 1st quarter valued at about $182,000. 68.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Needham & Company LLC reissued a "hold" rating on shares of InMode in a report on Wednesday, July 30th. Canaccord Genuity Group reissued a "hold" rating and issued a $15.00 price target on shares of InMode in a report on Friday, July 11th. Finally, Barclays lowered their price target on shares of InMode from $24.00 to $21.00 and set an "overweight" rating on the stock in a report on Wednesday, July 30th. One equities research analyst has rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $18.04.

InMode Stock Performance

Shares of NASDAQ:INMD traded down $0.04 during mid-day trading on Tuesday, reaching $14.82. 201,961 shares of the company's stock were exchanged, compared to its average volume of 1,242,571. The firm has a market capitalization of $936.77 million, a price-to-earnings ratio of 6.00 and a beta of 2.00. The business's fifty day moving average price is $14.52 and its 200-day moving average price is $15.20. InMode Ltd. has a twelve month low of $13.14 and a twelve month high of $19.85.

InMode (NASDAQ:INMD - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The healthcare company reported $0.47 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.03). The business had revenue of $95.60 million for the quarter, compared to analyst estimates of $98.45 million. InMode had a return on equity of 18.38% and a net margin of 44.50%.InMode's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.34 EPS. Analysts predict that InMode Ltd. will post 1.75 EPS for the current fiscal year.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.